M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 2.88 USD 1.41% Market Closed
Market Cap: 305.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-23%
Revenue
Forecast
+8%
Operating Income
Forecast
+44%
Net Income
Forecast
+9%

Wall Street
Price Targets

MXCT Price Targets Summary
MaxCyte Inc

Wall Street analysts forecast MXCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MXCT is 7.48 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

MXCT Lowest Forecast
Wall Street Target
6.06 USD
110% Upside
MXCT Average Forecast
Wall Street Target
7.48 USD
160% Upside
MXCT Highest Forecast
Wall Street Target
9.45 USD
228% Upside
Lowest
Price Target
6.06 USD
110% Upside
Average
Price Target
7.48 USD
160% Upside
Highest
Price Target
9.45 USD
228% Upside
MaxCyte Inc Competitors:
Price Targets
S
237690
ST Pharm Co Ltd
60% Upside
CGEN
Compugen Ltd
227% Upside
RPID
Rapid Micro Biosystems Inc
263% Upside
G
GENO
Genovis AB
64% Upside
S
237690
ST Pharm Co Ltd
60% Upside
CGEN
Compugen Ltd
227% Upside
RPID
Rapid Micro Biosystems Inc
263% Upside
G
GENO
Genovis AB
64% Upside
NEO
Neogenomics Inc
80% Upside
DHR
Danaher Corp
27% Upside
R
RVU
Ryvu Therapeutics SA
151% Upside
688222
HitGen Inc
12% Upside

Revenue
Forecast

Revenue Estimate
MaxCyte Inc

For the last 8 years the compound annual growth rate for MaxCyte Inc's revenue is 15%. The projected CAGR for the next 3 years is 33%.

15%
Past Growth
33%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
MaxCyte Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
MaxCyte Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
MXCT intrinsic value, competitors valuation, and company profile.
DCF Valuation
MXCT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MXCT stock valuation using valuation multiples.
Wall Street Estimates
MXCT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MXCT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MXCT's stock price target?
Price Target
7.48 USD

According to Wall Street analysts, the average 1-year price target for MXCT is 7.48 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

What is MaxCyte Inc's Revenue forecast?
Projected CAGR
33%

For the last 8 years the compound annual growth rate for MaxCyte Inc's revenue is 15%. The projected CAGR for the next 3 years is 33%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.